Rogeneous nuclear ribonucleoprotein A1; HNRNPA2B1: heterogeneous nuclear ribonucleoprotein A2/B > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Rogeneous nuclear ribonucleoprotein A1; HNRNPA2B1: heterogeneous nuclear ribonucleoprotein A2/B1; HNRNPH1: heterogeneous nuclear ribonucleoprotein H1; HNRNPK: heterogeneous nuclear ribonucleoprotein K; HNRNPL: heterogeneous nuclear ribonucleoprotein L; HSPD1: heat shock 60-kDa protein 1; KHSRP: KH-type splicing regulatory protein (far upstream element-binding protein 2); LMNA: lamin A/C; POLR2A: polymerase (RNA) II (DNA-directed) polypeptide A; POLR2E: polymerase (RNA) II (DNA-directed) polypeptide E; PRDX2: peroxiredoxin 2; RBBP4: retinoblastoma-binding protein 4; RUVBL1: RuvB-like 1; SOD2: superoxide dismutase 2, mitochondrial; SSc: systemic sclerosis; STMN1: stathmin 1; TBP: TATA box-binding protein; TGFB1: transforming growth factor b1; TOP1: topoisomerase (DNA) I; TPI1: triosephosphate isomerase 1; VIM: vimentin.Recherche Clinique from the Assistance Publique-H itaux de Paris for supporting Contrat d'Investigation et de Recherche Clinique 05066, HTAP-Ig. We also thank the Association des Scl odermiques de France, the PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/15501003 Groupe Fran is de Recherche sur la Scl odermie and the Unit?de Recherche Clinique Cochin-Necker. Author details 1 Institut Cochin, Universit?Paris Descartes, CNRS UMR 8104, 8 rue M hain, F-75014 Paris, France. 2INSERM U1016, 8 rue M hain, F-75014 Paris, France. 3 Institut Cochin, Plate-forme Prot mique de l'Universit?Paris Descartes, CNRS UMR 8104, 22 rue M hain, F-75014 Paris, France. 4Etablissement Fran is du Sang, h ital Saint-Vincent de Paul, Assistance PubliqueH itaux de Paris, 82 avenue Denfert-Rochereau, F-75674 Paris Cedex 14, France. 5Universit?Paris Descartes, Facult?de M ecine, p e de M ecine Interne et Centre de r ence pour les vascularites n rosantes et la scl odermie syst ique, h ital Cochin, Assistance Publique-H itaux de Paris, 27 rue du Faubourg Saint-Jacques, F-75679 Capecitabine Paris Cedex 14, France. Authors' contributions GB participated in study design, performed most of the experiments and drafted the manuscript. HD contributed to the experiments and revised the manuscript. MCT contributed to the study design and the interpretation of data and revised the manuscript. CB and LC performed mass spectrometry experiments and revised the manuscript. CF performed Pathway Studio analysis and revised the manuscript. GW supervised the recruitment of healthy blood donors and revised the manuscript. LG supervised the recruitment of patients with systemic sclerosis and revised the manuscript. LM directed the study design, supervised the recruitment of patients with systemic sclerosis, contributed to the interpretation of data and drafted the manuscript. All authors read and approved the final manuscript. Competing interests The authors declare that they have no competing interests. Received: 7 February 2011 Revised: 13 April 2011 Accepted: 13 May 2011 Published: 13 May 2011 References 1. Tamby MC, Chanseaud Y, Guillevin L, Mouthon L: New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003, 2:152-157. 2. Steen VD: Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42. 3. Gabrielli A, Avvedimento EV, Krieg T: Scleroderma. N Engl J Med 2009, 360:1989-2003. 4. Chizzolini C, Raschi E, Rezzonico R, Testoni C, Mallone R, Gabrielli A, Facchini A, Del Papa N, Borghi MO, Dayer JM, Meroni PL: Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002, 46:1602-1613. 5. Baroni SS, Santillo M, Bevilacqu.